Table 6.
Vaccines administrated against SARS-CoV-2 infection and relative immunization (anti-Spike protein IgG concentration in the sera of the individuals).
| Comparison of Antibody Concentration (p-Value) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vaccine | Frequency n (%) | Antibody Concentration (AU/mL) * | Pfizer | Moderna | AstraZeneca | Janssen | Pfizer/Moderna | Pfizer/AstraZeneca | Pfizer/Janssen | Moderna/AstraZeneca | Moderna/Janssen | CoronaVac |
| Pfizer a | 964 (64.3) | 377.29 [365.11–389.48] |
- | NS *** | p < 0.001 **** | p < 0.001 | NS | p = 0.006 | NS | p = 0.004 | NS | NS |
| Moderna b | 171 (11.4) | 424.92 [403.08–446.75] |
- | - | p < 0.001 | p < 0.001 | NS | NS | NS | NS | NS | NS |
| AstraZeneca c | 100 (6.7) | 161.82 [118.25–205.38] |
- | - | - | NS | p < 0.001 | p < 0.001 | p < 0.001 | p < 0.001 | p < 0.001 | NS |
| Janssen d | 41 (2.7) | 233.30 [157.73–308.88] |
- | - | - | - | p = 0.018 | p < 0.001 | p < 0.001 | p < 0.001 | p < 0.001 | NS |
| Pfizer/Moderna | 12 (0.8) | 462.29 [404.30–520.29] |
- | - | - | - | - | NS | NS | NS | NS | NS |
| Pfizer/AstraZeneca | 103 (6.9) | 455.19 [432.10–478.28] |
- | - | - | - | - | - | NS | NS | NS | NS |
| Pfizer/Janssen | 24 (1.60) | 462.01 [410.32–513.71] |
- | - | - | - | - | - | - | NS | NS | NS |
| Moderna/AstraZeneca | 61 (4.10) | 480.88 [458.18–503.58] |
- | - | - | - | - | - | - | - | NS | NS |
| Moderna/Janssen | 22 (1.50) | 463.42 [412.68–514.16] |
- | - | - | - | - | - | - | - | - | NS |
| CoronaVac e | 1 (0.10) | 470.50 ** | - | - | - | - | - | - | - | - | - | - |
a BTN162b2—Pfizer/BioNTech. b mRNA-1273—Moderna. c AZD1222—Oxford/AstraZeneca. d Ad26.COV2.S—Janssen (Johnson & Johnson). e CoronaVac—Sinovac. * Values are expressed as mean [95% Confidence Interval]. ** Confidence interval not presented as only one participant was inoculated with this vaccine. *** NS–statistically non-significant. **** Results with statistical significance are highlighted in bold.